Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA Approves NDA For Zogenix’ Sumavel DosePro
Zogenix has got approval from the US FDA for its New Drug Application (NDA) on Sumavel DosePro (sumatriptan injection) needle-free delivery system. It is to treat acute migraine,
Zogenix has got approval from the US FDA for its New Drug Application (NDA) on Sumavel DosePro (sumatriptan injection) needle-free delivery system. It is to treat acute migraine,
Biolex has provided the preclinical results demonstrating that the thrombolytic activity of the company’s full-length recombinant human plasmin (BLX-155), was superior to t-PA in a preclinical study. BLX-155
The specialty chemicals Group, ALTANA has entered into an agreement to acquire the business of the Water Ink Technologies. Within the ALTANA Group, Water Ink Technologies will be
Mylan has received approval from the FDA for its Abbreviated New Drug Application (ANDA), for Liothyronine Sodium Tablets USP, 5 mcg (base), 25 mcg (base) and 50 mcg
Biostar has received approval from local government to produce Yizi Capsules, Tangning Capsules, and Shengjing Capsules. The company is ready to launch these products through its domestic market
Zila has issued the following response to a complaint filed in the Delaware Court of Chancery by Intelident: “Zila is disappointed that Intelident is using a litigation strategy
Sanofi-Aventis has released a report by a multidisciplinary board of renowned international experts, following an in-depth assessment of the recent publications of registry analyses with Lantus in Diabetologia.
Ivax has signed an amended distribution agreement with Immco. The agreement provides Diamedix rights to distribute Immco’s portfolio of products in the US, with additional strategic initiatives related
Watson Laboratories (Watson), a subsidiary of Watson, has filed an Abbreviated New Drug Application (ANDA) with the FDA. The company is seeking approval to market its trospium chloride
Array BioPharma has announced the filing of an investigational new drug (IND) application with the FDA, to initiate a phase 1 clinical trial in cancer patients with MEK